drugset / Trial / NCT05178654

Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]PF-07321332 in Healthy Male Participants.

NCT05178654

Phase 1 Withdrawn Pfizer
RandomizedSingle-groupOpen-labelBasic science

Summary

This study is to characterize mass balance and further the understanding of human pharmacokinetics, metabolism, and excretion of radiolabeled \[14C\]PF-07321332 in healthy male participants following oral administration with ritonavir.

Timeline

Start
2022-02-22
Primary completion
2022-04-01
Completion
2022-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Nirmatrelvir Small molecule 100 unknown Oral
Subject Nirmatrelvir Small molecule 300 mg Oral
Background Ritonavir Other / unclassified 100 mg

Indications

No indication recorded.